Ocular Genomics
243 Charles Street Boston, MA 02114 Contact us
Diagnostic Testing
Support our research
Explore our labs
Ocular Genomics MENU
Ocular Genomics
  • Meet the Team
  • Services
    • Biobank Core Services
    • Bioinformatics and Statistics Core
    • Functional Genomics (Zebrafish) Core
    • Gene Transfer Vector
      • Rates
      • Order Information
      • Contact Us
    • Genetic Diagnostic Testing Service
      • Pricing
    • Genomics Core Services
      • Sample Processing
      • Sequencing
      • Other Genomics Services
    • IRD service
  • Labs
    • Amamoto lab
      • Lab Members
    • Biobank Core
    • Bujakowska Lab
      • Lab Members
      • Publications
    • Comander Lab
      • Lab Members
      • Publications
    • Engle Lab
    • Functional Genomics Core (Zebrafish Facility)
      • Lab Members
    • Genetic Counseling Team
      • Team Members
    • Genomics Core Lab
      • Lab Members
    • iPS Research Lab
      • Lab Members
      • Grant support
      • Publications
    • Liu Lab
      • Lab Members
      • Publications
      • Projects
    • Mary Whitman Lab
      • Lab Members
    • MEEI Bioinformatics Center (MBC)
      • Lab Members
    • Pierce Lab
      • Lab Members
      • Publications
      • Projects
    • Segrè Lab
      • Selected Publications
    • Vandenberghe Lab
      • Lab Members
    • Wiggs Lab
      • Lab Members
  • News & Publications
    • RETINAL Transcriptome
  • Affiliates
  • Careers
  • Home
  • News
  • GEDI Panel Released at MEEI

Recent Posts

  • Francesca Kim wins ARVO outstanding poster award
  • Friedenwald Award Lecture presented by OGI member Connie Cepko at ARVO 2025 annual meeting
  • Findings highlight the significance of Vascular Endothelial Protein Tyrosine Phosphatase in diverse ocular and systemic veno-vascular diseases.
  • Extracellular Vesicle RNAs as Biomarkers for Inherited Retinal Degenerations
  • BRILLIANCE Trial shows CRISPR Gene Editing Found Safe and Effective for Treating Patients with rare genetic disorder.

Archives

  • May 2025
  • March 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • July 2024
  • June 2024
  • May 2024
  • January 2024
  • October 2023
  • July 2023
  • June 2023
  • May 2023
  • March 2023
  • February 2023
  • December 2022
  • November 2022
  • June 2021
  • May 2021
  • March 2021
  • February 2021
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • June 2020
  • August 2019
  • May 2019
  • April 2019
  • May 2018
  • April 2018
  • March 2018
  • November 2017
  • September 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017

Categories

  • News
  • Publication

GEDI Panel Released at MEEI
May 1, 2017

The Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology today announced the availability of a comprehensive genetic diagnostic test for inherited retinal disease (IRD), early-onset glaucoma and optic atrophy.

The Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology today announced the availability of a comprehensive genetic diagnostic test for inherited retinal disease (IRD), early-onset glaucoma and optic atrophy. The Genetic Eye Disease, or GEDi, panel uses targeted enrichment coupled with next-generation sequencing (NGS) to simultaneously analyze the coding sequence and selected intronic regions of 234 genes associated with IRD, early-onset glaucoma and optic atrophy, as well as the mitochondrial genome, for likely-pathogenic mutations. Mass. Eye and Ear is the first and only location in Boston and in the northeast to offer this service.

Simultaneously deep sequencing the coding and intronic regions of these 234 genes, as well as the mitochondrial genome, allows for a comprehensive and unbiased genetic analysis of patient samples. This combination of sequencing is especially relevant considering the high degree of genetic heterogeneity associated with IRD. Providing clinicians and patients with accurate GEDi genetic diagnoses can improve genetic counseling and facilitate focal ocular treatments and therapies, including corrective gene therapy clinical trials.

“We are thrilled to be able to offer this thorough clinical genetic diagnostic testing to our patients and to the ophthalmic care community in general,” said Dr. Eric Pierce, Director of the Ocular Genomics Institute (OGI) at Mass. Eye and Ear/Harvard Medical School Department of Ophthalmology. “We find the comprehensive testing valuable as genetic diagnoses can be more accurate than those that are based on clinical features alone.”

The GEDi diagnostic panel is subdivided into two separate tests: GEDi-R for IRD’s (226 genes), and GEDi-O for early-onset glaucoma and optic atrophy (8 genes). Both GEDi genetic diagnostic tests have been validated in compliance with Clinical Laboratory Improvement Amendment (CLIA) requirements, and are offered through the OGI’s CLIA-certified Genetic Diagnostic Laboratory. GEDi targeted regions are covered at 97% at 10x NGS depth-of-coverage. .


— BOSTON, Mass., October 18, 2013

About Massachusetts Eye and Ear

Massachusetts Eye and Ear clinicians and scientists are driven by a mission to find cures for blindness, deafness and diseases of the head and neck.  After uniting with Schepens Eye Research Institute, Mass. Eye and Ear in Boston became the world’s largest vision and hearing research center, offering hope and healing to patients everywhere through discovery and innovation.  Massachusetts Eye and Ear is a Harvard Medical School teaching hospital and trains future medical leaders in ophthalmology and otolaryngology, through residency as well as clinical and research fellowships.  Internationally acclaimed since its founding in 1824, Massachusetts Eye and Ear employs full-time, board-certified physicians who offer high-quality and affordable specialty care that ranges from the routine to the very complex.  U.S. News & World Report’s “Best Hospitals Survey” has consistently ranked the Mass. Eye and Ear Departments of Otolaryngology and Ophthalmology as among the top hospitals in the nation and this year ranked as number one.

About the Ocular Genomics Institute (OGI)

The primary goal of the OGI is to translate the promise of personalized genomic medicine into clinical care for ophthalmic disorders.

The OGI is working to achieve this goal via a combination of:

  • Laboratory-based translational research,
  • Application of modern genomic technologies to improve clinical genetic diagnosis and identification of new disease genes,
  • Clinical research directed towards clinical trials of novel genetic therapies, and
  • Provision of state-of-the-art clinical care for patients with ophthalmic genetic disorders.
  • Training programs in ophthalmic genetics for medical students, graduate students and clinical fellows.

The OGI is proud to be affiliated with such a renowned institution as Massachusetts Eye and Ear, and strives to continue its legacy of excellence. It is our hope that the evolvement of the OGI will put Massachusetts Eye and Ear and Harvard Medical School at the forefront of progressive genomic research and the development of rational therapies, ultimately making it one of the premier centers in the world for the treatment of inherited ophthalmic disorders.

Featured:

Contact Us

243 Charles Street
Boston, MA 02114

Labs

  • Amamoto lab
  • Biobank Core
  • Bujakowska Lab
  • Comander Lab
  • Engle Lab
  • Functional Genomics Core (Zebrafish Facility)
  • Genetic Counseling Team
  • Genomics Core Lab
  • iPS Research Lab
  • Liu Lab
  • Pierce Lab
  • Segrè Lab
  • Vandenberghe Lab
  • Whitman Lab
  • Wiggs Lab

Sitemap

  • Affiliates
  • Careers
  • Meet the Team
  • News & publications
  • Support Our Research
  • Services
  • Privacy
website-boston WebsiteBoston